Article Text
Editorial
Lipid lowering in primary prevention: time to focus on young patients
Statistics from Altmetric.com
Footnotes
Contributors Dr GMG contributed to the planning and conduct of the article Dr AH contributed to the bibliography and writing of the article.
Funding Dr. GMG is supported by the Fonds de la Recherche du Québec - Santé (Junior 1 Clinical Research Scholar).
Competing interests Dr. GMG reports speaker/advisory board fees from Novartis, Bayer, Canadian Association of Interventional Cardiology, KYE, CSI, Boston Scientific, Pharmascience and JAMP Pharma; and research funds from the Fonds de Recherche du Québec - Santé, Canadian Institutes of Health Research, Bayer and Boston Scientific. None are related to the current manuscript.
Provenance and peer review Commissioned; internally peer reviewed.
Linked Articles
- Cardiac risk factors and prevention